| Not Yet Recruiting | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies Solid Tumors | Phase 2 | 2026-05-16 |
| Recruiting | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Carcinoma, Non-Small-Cell Lung | Phase 3 | 2025-04-24 |
| Completed | Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets Healthy Volunteers | Phase 1 | 2025-02-04 |
| Active Not Recruiting | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung | Phase 2 | 2024-02-16 |
| Terminated | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Can Solid Tumor, Adult, NSCLC, Advanced Cancer | Phase 1 | 2023-08-07 |
| Completed | A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib Healthy Adults | Phase 1 | 2023-06-29 |
| Completed | A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib Healthy Adults | Phase 1 | 2023-06-01 |
| Terminated | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer | Phase 1 | 2023-03-06 |
| Terminated | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer | Phase 1 | 2022-12-02 |
| Recruiting | Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Advanced NSCLC, Metastatic Lung Cancer | Phase 2 | 2022-11-22 |
| Completed | PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor. Healthy Adults | Phase 1 | 2022-02-02 |
| Completed | Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) Advanced Solid Tumor | Phase 1 | 2022-01-20 |
| Terminated | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon | Phase 1 | 2021-07-28 |
| Completed | A Study to Explore the Effect of Acid-reducing Agents Healthy Adults | Phase 1 | 2021-07-07 |
| Completed | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study Advanced or Metastatic Solid Malignancies | Phase 2 / Phase 3 | 2021-06-29 |
| Active Not Recruiting | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS Advanced Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | 2021-06-24 |
| Completed | PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates Advanced Solid Tumor | Phase 1 | 2021-04-08 |
| Completed | A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib Healthy Adults | Phase 1 | 2021-03-15 |
| Completed | A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitrava Hepatic Impairment | Phase 1 | 2021-03-12 |
| Active Not Recruiting | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KR Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | Phase 3 | 2021-02-23 |
| Recruiting | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | 2020-12-02 |
| Completed | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or O Clear-Cell Renal Cell Carcinoma | Phase 1 | 2020-08-11 |
| Completed | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease | Phase 1 | 2020-04-07 |
| Completed | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cel Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | 2019-07-15 |
| Active Not Recruiting | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease | Phase 1 / Phase 2 | 2019-01-15 |
| Completed | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma | Phase 2 | 2018-10-10 |
| Terminated | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Adv Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter | Phase 2 | 2018-09-11 |
| Terminated | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Carcinoma, Non-Small-Cell Lung | Phase 2 | 2016-11-07 |
| Terminated | Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC Advanced Cancer | Phase 1 / Phase 2 | 2016-06-01 |
| Completed | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in ME Non-Small Cell Lung Cancer | Phase 2 | 2015-10-01 |
| Completed | Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes Urothelial Carcinoma | Phase 2 | 2014-10-01 |
| Completed | Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer Advanced Cancer | Phase 1 | 2014-08-01 |
| Completed | Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2013-12-01 |
| Completed | Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State Advanced Malignancies | Phase 1 | 2013-08-01 |
| Completed | Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers Healthy | — | 2011-12-01 |
| Terminated | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Advanced Malignancies, Non-small Cell Lung Cancer | Phase 1 | 2009-08-01 |
| Terminated | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acut Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | 2008-06-01 |
| Completed | Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies Advanced Cancer | Phase 1 | 2008-06-01 |
| Completed | Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies Advanced Malignancies | Phase 1 | 2008-04-01 |
| Terminated | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgki Hodgkin Lymphoma, Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma) | Phase 2 | 2007-10-01 |
| Terminated | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cance Breast Cancer, Lung Cancer, Pulmonary Cancer | Phase 1 | 2007-08-01 |
| Completed | A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia Lymphocytic Leukemia, Chronic | Phase 2 | 2007-01-01 |
| Completed | A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine Tumors | Phase 1 / Phase 2 | 2006-09-01 |
| Terminated | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Di Myelogenous Leukemia, Acute, Myelodysplastic Syndromes | Phase 2 | 2006-09-01 |
| Terminated | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma Hodgkin's Lymphoma | Phase 2 | 2006-08-01 |
| Completed | Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma Lymphoma | Phase 2 | 2006-08-01 |
| Completed | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or A Myelodysplastic Syndrome, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | 2006-01-01 |
| Completed | A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes Leukemia, Myelodysplastic Syndromes | Phase 1 | 2005-02-01 |
| Completed | A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes Leukemia, Myelodysplastic Syndromes | Phase 1 | 2005-02-01 |
| Completed | Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Tumors, Non Hodgkin's Lymphoma | Phase 1 | 2004-04-01 |